Genes that are commonly deregulated in cancer are clinically attractive as candidate pandiagnostic markers and therapeutic targets. To globally identify such targets, we compared Cap Analysis of Gene Expression (CAGE) profiles from 225 different cancer cell lines and 339 corresponding primary cell samples to identify transcripts that are deregulated recurrently in a broad range of cancer types. Comparing RNA-seq data from 4,055 tumors and 563 normal tissues profiled in the TCGA and FANTOM5 datasets, we identified a core transcript set with theranostic potential. Our analyses also revealed enhancer RNAs which are upregulated in cancer, defining promoters which overlap with repetitive elements (especially SINE/Alu and LTR/ERV1 elements) that are often upregulated in cancer. Lastly, we documented for the first time upregulation of multiple copies of the REP522 interspersed repeat in cancer. Overall, our genome-wide expression profiling approach identified a comprehensive set of candidate biomarkers with pancancer potential, and extended the perspective and pathogenic significance of repetitive elements which are frequently activated during cancer progression.
Introduction
Successful cancer treatment depends heavily on early detection and diagnosis. Despite decades of research, relatively few biomarkers are routinely used in clinics, (e.g. and PSA in ovarian and prostate cancers respectively (1,2)).There is a need for reliable and clinically applicable new cancer biomarkers for early detection. Cancers originating in the same tissue can be very heterogeneous, often being derived from different cell types and having drastically different mutation profiles (3). At the same time, cancers from different tissues can share some common features, e.g. The Cancer Genome Atlas (TCGA) has found genes and pathways, DNA copy number alterations, mutations, methylation and transcriptome changes that recur across 12 different primary tumor types (4).
Here using Cap Analysis of Gene Expression (CAGE) data collected for the FANTOM5 (Functional ANnoTation Of Mammalian genomes) project (5) we identified mRNAs, long-non-coding RNAs (lncRNAs), enhancer RNAs (eRNAs) and RNAs initiating from within repeat elements, that are recurrently perturbed in cancer cell lines.
To confirm that these transcripts are relevant to tumors we compared their expression in 4,055 primary tumors and 563 matching tissue sets RNA-seq profiled by the TCGA (6) and in a set of colorectal tumor (7) samples profiled proteomically. Finally, for the most promising biomarker candidates we performed qRTPCR validations in cancer cell lines and tumor cDNA panels. Taken together, our analyses allowed for identification of a set of robust pan cancer biomarker candidates, which have the potential for development as blood biomarkers for early detection and for histological screening of biopsies.
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This work is part of the FANTOM5 project. Data download, genomic tools and copublished manuscripts have been summarized at the FANTOM5 website (8).
Materials and Methods

FANTOM5 data
We used the cap analysis of gene expression (CAGE) data from the FANTOM5 project (libraries sequenced to a median depth of 4 million mapped tags) (5). We used 564 CAGE profiles: 225 cancer cell lines and 339 primary cells samples. We split the data into 3 data sets: a) matched solid b) unmatched solid and c) matched blood (Supplementary table 1A and C for list of cancer types and sample annotation), The CAGE tags counts under 184,827 robust DPI clusters (decomposition-based peak identification(5)) were used to represent a promoter-level expression. For the enhancer activity, we used the CAGE tags counts under 43,011 enhancer regions identified in (9) .
FANTOM5 differential expression analysis
To identify up and down regulated transcripts in cancer cell lines versus normal primary cells we used Genewise Negative Binomial Generalized Linear Models as implemented in edgeR (10) . The cancer vs. normal comparison was performed using glmLRT function.
In matched solid comparison we set equal weight for each solid cancer type, each type contributing equally to overall comparison. In unmatched solid and matched blood dataset, simple cancer cancer vs normal comparison was peformed.
The p-values were adjusted for multiple testing by Benjamini-Hochberg method. The thresholds of fold change > 4 and FDR < 0.01 were used.
ON/OFF analysis
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For each feature, we determined the expression status in binary fashion: ON (expressed, count > 0), OFF (not detected, count = 0). We then calculated the frequency of expression in cancer and normal samples. Features expressed 4 times more frequently in cancer that in normal samples mere selected as "ON in cancer, while features not expressed/lost 4 times more often in cancer than in normal samples mere selected as "OFF in cancer. The procedure was applied to each dataset (matched solid, unmatched solid and matched blood). The significance of the association (contingency) between ON/OFF status and cancer/normal status was tested by 2-sided Fisher's exact test with adjustment for multiple testing by Benjamini-Hochberg method. The threshold of FDR < 0.01 was used. The pipeline of differential expression described above was applied separately to the DPI/promoter counts and enhancer counts. The features found differentially expressed all 3 datasets were selected as "pan" cancer features, whereas features differentially expressed in matched and unmatched solid datasets only were selected as "solid only" cancer features.
TCGA RNA-seq data
We obtained the RNA-Seq profiling data of 4055 cancer samples and 563 normal tissues data from The Cancer Genome Atlas (TCGA) Data Portal (data status as of Aug 5, 2013, origin listed in Supplementary table 1B) (6). The profiles represented 14 solid cancer type for which both tumor and normal tissue samples were available. We downloaded level3 RNASeqV2, upper quartile normalized RSEM count estimates with expression profiles of 20531 genes in 4618 samples.
The counts were log2 transformed and used as an input expression data to LIMMA.
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The cancer vs. normal comparison was performed using equal weight for each solid cancer type, each type contributing equally to overall comparison. The p-values were adjusted for multiple testing by Benjamini-Hochberg method. The thresholds of fold change > 2 and FDR < 0.01 were used.
Enrichment for cancer related genes.
We tested for the enrichment by applying hyper geometric test, using the significance threshold of p-value < 0.05. The list of oncogenes was a union of oncogenes listed in MSigDB (11) and UniProt (12) databases. For tumor suppressors, we considered genes listed in at least two of three sources: MSigDB (11), UniProt (12) and TSGene (13) tumor suppressor list. For the list of genes frequently mutated in cancer we used the High Confidence Drivers mutated across 12 cancer types from Tamborero et al. (14) . We also tested for enrichment of cancer related genes listed in COSMIC: Cancer Gene census (15) .
Chia-PET Enhancer-promoter pairs
We obtained the Chromatin Interaction Analysis Paired-End Tags (ChIA-PET) data from ENCODE/GIS-Ruan project (GSE39495, April 21, 2014). Data files from 15 experiments covered 5 cell lines (Hct-116, Helas3, K562, Mcf7 and Nb4) and 3 transcription factors (Pol2, Ctcf, ERalpha a). We merged the interaction from all experiments. We then extracted the ChIA-PET interaction clusters overlapping the genomic locations of enhancers and searched if the linked genomic locations overlap promoters of the annotated genes.
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Quantitative PCR (qPCR) for cell line samples and human cancer/normal tissue cDNA Five hundred nanograms of total RNA from K562, HepG2, MCF7, and HDF was reverse-transcribed using oligo dT primer, which was then diluted 12.5 times with DNA/RNA free water. Primers for real-time PCR were designed by Primer3 web tool (Supplementary Table 12 Firstly, the cancer cell line and primary cell datasets were divided into three subsets (see Supplementary table 1A) ; cell-lines and primary cells from solid tissues or blood lineages that could be matched are referred to as matched-solid or matched-blood.
The remaining samples from solid tissue are referred to as unmatched-solid.
In each subset, we identified promoters that were differentially expressed between cancer and normal (edgeR(10), >4 fold change, FDR < 0.01). We also performed an alternative binary analysis (we refer to as an ON/OFF analysis) to identify transcripts that were consistently switched off or switched on in cancer (4 times more often expressed In some cases the CAGE analysis identified alternative promoters. Comparing the gene wise differential expression for individual promoters compared to the total CAGE signal for the same gene ( Figure 1C) , we found that for 23% of differentially expressed protein coding genes, at least one alternative promoter behaved differently to that of the whole gene, whereas for lncRNAs (which have fewer alternative promoters) it was only 5% ( Figure 1D 
Potential pan cancer biomarkers
We found that 76 (17%) of the up-regulated genes identified in the cancer cell lines analysis were also up-regulated in primary tumors from TCGA (Figure 2 ). Among them we find oncogenes (HOXC13, MYEOV, MNX1 and CASC5), cancer antigens (PRAME, CD70, CASC5, IDF2BP3) and, somewhat unexpectedly, the tumor suppressors (TP73, BLM, BUB1B). The up-regulated genes were also enriched in genes involved in cell cycle, DNA metabolism, biopolymer metabolism and homeobox genes involved in development. This included well-known pan cancer genes such as TERT, PRAME and TOP2A (17, 18) and MYEOV and MNX1 which are implicated in blood malignancies (19, 20) and FAM111B in prostate cancer (21). There were 108 genes that were down regulated at the protein level and in at least one transcriptome analysis (CAGE or RNA-seq). Strikingly, the top ten enriched terms within those genes were all related to metabolic processes, either to oxidative processes or lipid metabolism (Supplementary figure 2B) , thereby confirming the metabolic pathway changes that we have observed from the RNA data. 
Pan cancer long non coding RNAs
Deregulated long non-coding RNAs located near cancer related genes
We next looked at the genomic neighborhood of the differentially expressed lncRNAs.
For 27 of the 181 (GENCODE19) differentially expressed lncRNAs we found 33 cancer figure 3) . For example PVT1 neighbors MYC; these are consistently co-gained in cancer. We also observe RP11-1070N10.5 neighboring the TCL6 (lincRNA), TCL1A and TCL1B oncogenes (located in a breakpoint cluster region on chromosome 14q32 in T-cell leukemia (26)) and HOXA11-AS, neighboring HOXA13 and HOXA9 and overlapping the HOXA11 oncogene. Notably 5 out of 6 cancer related genes located within 1kb from up-regulated lncRNAs were also up-regulated, these include the MCF2L, GATA2, MNX1 oncogenes and BSG, CSAG1 cancer antigens ( Table 2) . Possibly linked to cancer metabolism, the up-regulated PCAT7 is located antisense to FBP2 (fructose-1,6-bisphosphatase-2) (Supplementary figure 3), whose decreased expression promotes glycolysis and growth in gastric cancer cells (27).
Activation of repeat elements in cancer
Globally about 20% of all FANTOM5 promoters initiate from within repetitive elements and low complexity DNA sequences annotated by RepeatMasker. We observed a simple relationship for promoters that overlapped a repetitive element; the higher the fold change (up-regulation in cancer) the higher the probability that the promoter overlapped a Table 3) .
In contrast, the majority of promoters overlapping simple repeats and low complexity sequences were associated with protein coding transcripts. Simple repeats were enriched amongst up regulated promoters, while low complexity sequences were enriched amongst down-regulated promoters ( Table 3) .
Bidirectional transcription from REP522 satellite repeat is activated in cancer.
Interestingly, a specific repeat family, REP522, was strongly enriched in the most upregulated promoters. REP522, originally called a telomeric satellite, is a largely palindromic, unclassified interspersed repeat of ~1.8Kb in size (28). We observed that out of 72 promoters overlapping REP522, 25 were up-regulated in cancer (odds ratio:
62.05). 20 out of these 25 promoters were associated with a known transcript (5 pseudogenes, 9 lncRNAs and 1 protein coding genes) including the pseudogene BAGE2 (B melanoma antigen family, member 2) and the lncRNAs PCAT7 and BRCAT95 which were previously implicated in cancer (23). In most cases the transcription is initiated bidirectionally and in 5 cases it overlaps regions previously annotated as enhancers. To show that the observed activation of REP522 elements was not due to a mapping artifact, we performed qPCR validation for 11 up-regulated, REP522 initiated transcripts from different genomic regions in 3 cancer cell lines and dermal fibroblast cells as a control.
For 8 of these we confirmed up-regulation in the cancer cell lines compared to normal fibroblasts ( Figure 4A) . In one case we confirmed the bidirectional transcription of CCD144NL and CCD144NL-AS1 from one REP522 element ( Figure 3B) 
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lowly expressed, novel and computationally assembled transcripts from miTranscriptome, hinting at the possibility that they were either too lowly expressed or the transcripts were not correctly assembled ( Figure 3C ). To our knowledge this is the first report implicating REP522 activation in cancer.
Enhancer activation in cancer
Taking advantage of the fact that CAGE data can be used to estimate the activity of enhancers from balanced bidirectional capped transcription (9), we performed differential expression analysis based on CAGE tags counts under 43,011 CAGE defined enhancers (9) using the same differential expression pipeline as for the promoter regions. We found 28 pan-cancer enhancers up regulated in solid and blood cancers and a further 62 up regulated in solid cancers only (Supplementary table 5) . Enhancers tend to be highly cell-type-specific (9); accordingly we found no broadly down regulated enhancers in cancer.
We found that 23 of the 90 up-regulated enhancers could be associated to a miTranscriptome transcript (5' end within 500bp from the enhancers) (Supplementary 
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(ING4, KCTD11) and 5 Mut-Drivers (PIK3CB, CLIP1, KIFC3, GPS2 and CARM1) (Supplementary table 6) . Additionally, 8 of the up-regulated enhancers were linked to promoters found to be up regulated in cancer cell lines, including cancer linked genes such as TNFSF12 and PIK3R3 (29) (Figure 3D ). As expected, there are differences in the genes sets identified by the two datasets.
Despite this we identified a core set of 128 markers that are consistently perturbed in both the FANTOM5 cell and TCGA tissue analyses. Four of the markers are also up regulated at the protein level in a colon cancer dataset. Specifically: TOP2A, MKI67, MCM2, and ASNS, which are amongst some of the most studied cancer biomarkers and drug targets.
TOP2A is targeted by etoposide (30)
. ASNS is targeted in asparginase therapy of acute lymphoblastic leukemia (31), and both MKI67 and MCM2 have been studied as biomarkers (32) and (33) and potential drug targets (34) and (35) . Targeting these genes is likely to bring therapeutic value to many patients as they are recurrently up regulated The FANTOM5 CAGE data also allowed us to look at transcript types rarely studied in prior efforts (long non-coding RNAs, enhancer RNAs and repetitive element derived RNAs). We report 271 pan-cancer lncRNAs, including famous cancer associated lncRNAs such as PVT1 and many novel cases. Public datasets confirmed the upregulation of 25 and down-regulation of 3 of these lncRNAs in at least two primary tumor types (23,24) and we further validated up-regulation of 2 novel lncRNAs by qRTPCR in a cDNA panel covering 8 tumor types. We also identify 90 enhancer RNA producing regions that are recurrently activated in cancer cell lines. For 4 of them a corresponding lncRNA transcript model is up-regulated in the TCGA dataset.
The observation that promoters that overlap repetitive elements are often up regulated in cancer is quite interesting, and the link of the little known REP522 element to cancer is novel. One instance of REP522 near the B melanoma antigen (BAGE) locus has been reported to be marked with H3K9me3 and actively transcribed (37), perhaps suggesting REP522 transcriptional activation is responsible for up-regulation of BAGE in cancer. Other better studied elements such as LTR elements have previously been reported to act as alternative promoters of host genes in mouse embryos (38) and to contribute to the complexity of the transcriptome of iPS and stem cells (39) . Thus the reactivation of these elements and the eRNAs identified above suggests acquisition of In conclusion, our results, which highlight the transcriptome changes in cancer and cover both protein coding genes, non-protein coding transcripts, unannotated promoters and enhancer RNAs, represent an important step towards discovery of potentially useful cancer biomarkers and therapeutic targets. Development of technologies to detect and target these molecules has the great potential to be applicable to a broad range of cancers. One last note is that we identify molecules that are consistently up or down in cancer normal comparisons, but are not necessarily always higher in all cancers relative to all normal tissues (a subset are). Such molecules may not be suitable for plasma/serum based diagnostics but would be useful in screening biopsies in a histopathological setting. BRCA  COAD  HNSC  KICH  KIRC  KIRP  LIHC  LUAD  LUSC  PRAD  READ  THCA  UCEC   PRAME  ZIC2  ZIC5  GABRD  HOXB13  OTX1  DLX4  DLX6  TERT  ONECUT2  HOXC13  FABP6  TNNT1  TP73  MNX1  E2F8  GRIN2D  DLX1  TOP2A  NMU  MMP13  CD70  KIF14  CENPF  PKMYT1  MKI67  EXO1  SRCIN1  MYEOV  SLCO1B3  IGF2BP3  FAM111B  BUB1B  TM4SF19  TMEM145  E2F7  POLQ  RAD54L  SKA3  CDC6  SGOL1  KIF18A  NUSAP1  MAST1  RHPN1  CBX2  CLSPN  SLC7A11  XRCC2  RDM1  CCNO  KRT80  GPR19  RNFT2  KIF23  PDX1  ATAD2  HELLS  MLF1IP  RCOR2  BLM  CCDC150  CCNE2  CASC5  CHRNA5  DNAH14  MCM2  ATAD5  PABPC1L  RACGAP1  KIFC2  CDC7  DBF4  RFC4  ASNS  MTHFD2   ACOX2  LYNX1  PTRF  CLIP3  SLIT3  BST1  JAM3  THBD  PTGS1  PEAR1  ANPEP  ARMCX1  BEX4  KCTD12  ZNF677  FBLN5  FLRT2  TWIST2  CXCL2  TNFAIP8L3  TMEM220  TIMP3  TSPYL5  MT1A  APOD  IGF2  DNALI1  SERPING1  GYPC  S1PR1  MYL9  NAALADL1  GPX3  SERP2  TPM2  OSR1  PHYHD1  NDN  PHYHIP  FEZ1  PCDHGA12  SRPX  MT1E  PAMR1  DCN  SFRP1  AOX1  FABP4  NKAPL  COX7A1  HSPB6 T091467   T091478   T091480  T091481   T091482  T091483  T091484  T091485   T091486   T091487   T091488 ( 
